7.41
-0.36 (-4.70%)
| Penutupan Terdahulu | 7.77 |
| Buka | 7.82 |
| Jumlah Dagangan | 422,717 |
| Purata Dagangan (3B) | 746,535 |
| Modal Pasaran | 220,442,896 |
| Harga / Pendapatan (P/E TTM) | 2.35 |
| Harga / Jualan (P/S) | 2.64 |
| Harga / Buku (P/B) | 2.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -7.57 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 333.06% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -65.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.59 M |
| Pulangan Atas Aset (ROA TTM) | -33.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -267.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Q32 Bio Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.00 |
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 6.57% |
| % Dimiliki oleh Institusi | 73.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Jun 2026 | 2,717,106 |
| Opaleye Management Inc. | 30 Jun 2026 | 931,000 |
| Logos Global Management Lp | 30 Jun 2026 | 800,000 |
| Woodline Partners Lp | 30 Jun 2026 | 286,212 |
| Sanofi | 30 Jun 2026 | 244,083 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KALOWSKI LEE | - | 8.11 | -1,301 | -10,551 |
| MORRISON JODIE POPE | - | 8.11 | -3,221 | -26,122 |
| VIOLETTE SHELIA M. | - | 8.11 | -917 | -7,437 |
| Jumlah Keseluruhan Kuantiti Bersih | -5,439 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -44,110 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 8.11 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KALOWSKI LEE | Pegawai | 06 Oct 2026 | Jual (-) | 1,301 | 8.11 | 10,551 |
| VIOLETTE SHELIA M. | Pegawai | 06 Oct 2026 | Jual (-) | 917 | 8.11 | 7,437 |
| MORRISON JODIE POPE | Pegawai | 06 Oct 2026 | Jual (-) | 3,221 | 8.11 | 26,122 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |